AstraZeneca Pays $200M Upfront for Ex-China Rights to Late-Phase COPD Drug Challenger
By Dr. Zubair Khalid, DVM, MS, PhD ·
Key Takeaways
- AstraZeneca has acquired ex-China rights to a late-phase drug candidate for chronic obstructive pulmonary disease (COPD) from Sino Biopharmaceutical for an upfront payment of $200 million, with potential total value reaching $2.1 billion.
- This acquisition positions AstraZeneca to compete with Merck & Co.'s Ohtuvayre (ensifentrine), a non-steroidal, inhaled therapy approved for maintenance treatment of COPD.
- The drug candidate is in late-stage development, indicating it has progressed through significant clinical trial phases and is nearing potential regulatory submission.
- COPD is a progressive lung disease characterized by airflow limitation and inflammation, representing a significant global health burden and a competitive pharmaceutical market.
- The development of new COPD therapies beyond standard bronchodilators and inhaled corticosteroids reflects ongoing efforts to address unmet needs for patients with persistent symptoms.
- Sino Biopharmaceutical retains rights to the drug candidate within China, a substantial market for respiratory therapeutics, while securing significant financial and developmental partnership.
AstraZeneca has agreed to pay Sino Biopharmaceutical $200 million upfront for rights outside China to a late-stage drug candidate that would compete with Merck & Co.’s chronic obstructive pulmonary disease (COPD) treatment Ohtuvayre. The overall deal could be worth up to $2.1 billion, according to the deal terms.
The drug is in late-phase development as a potential challenger to Ohtuvayre (ensifentrine), a non-steroidal, inhaled therapy that Merck acquired through its purchase of Verona Pharma in 2024. Ohtuvayre was approved in the U.S. in June 2024 for maintenance treatment of COPD, a progressive lung disease that affects millions worldwide. The new candidate provides AstraZeneca with a late-stage asset in the large and competitive COPD market.
COPD is a leading cause of morbidity and mortality globally, and the market has seen a wave of innovation in recent years with new mechanisms of action beyond standard bronchodilators and inhaled corticosteroids. The entry of a new challenger signals continued interest in expanding treatment options for patients who remain symptomatic on existing therapies. For Sino Biopharmaceutical, the deal provides a significant upfront payment and potential milestones while retaining rights in China, a major market for respiratory disease.
Source: original report